EGFR and non-small cell lung carcinoma: Several phase III clinical trials have reported promising median progression-free survivals (mPFS) (9–13 months) and tolerable side-effects in patients with EGFR-mutant advanced NSCLC receiving first-generation EGFR-TKIs [2–6].